Axa
OREX

Axa’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Axa’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,906
Closed -$363K – 1482
2013
Q3 		$363K Buy
5,906
+1,195
+25% +$80.9K ﹤0.01% 1059
2013
Q2 		$276K Buy
+4,711
New +$290K ﹤0.01% 1070

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa's OREX Position: Q4 2013 in Review

Axa sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 5,906 shares — an estimated $363K sold.

Axa first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $363K in Q3 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Axa reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Axa sold 5,906 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $363K.
  • Axa first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Axa's Orexigen Therapeutics, Inc. position peaked at $363K in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Axa's 13F filing for Q4 2013, filed 13 Feb 2014.